Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | GFER | P55789 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28171411 | 0.85 | KMT2A (0.46) | KMT2AMEN1MAPK1GAAGFER | |
| SCHEMBL15918604 | 0.79 | ACACB (0.52) | KMT2AMEN1GAAGFERTDP1 | |
| SCHEMBL353475 | 0.79 | — | — | |
| SCHEMBL4066379 | 0.79 | — | — | |
| SCHEMBL18176138 | 0.78 | ACACB (0.56) | KMT2AMEN1MAPK1ALDH1A1ACACB | |
| SCHEMBL13527463 | 0.78 | KMT2A (0.51) | KMT2AMEN1MAPK1GAAGFER | |
| SCHEMBL9973793 | 0.77 | GAA (0.48) | KMT2AMEN1MAPK1GAAGFER | |
| SCHEMBL7264104 | 0.76 | KMT2A (0.50) | KMT2AMEN1MAPK1GAAGFER | |
| SCHEMBL2605496 | 0.75 | KMT2A (0.44) | KMT2AMEN1MAPK1GAAGFER | |
| SCHEMBL2574566 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
| US-9663466-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | KMT2A 1638/4885MEN1 4845/4885MAPK1 1512/4885 |
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | KMT2A 155/4885MEN1 2323/4885MAPK1 1083/4885 |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | KMT2A 155/4885MEN1 2323/4885MAPK1 1083/4885 |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | KMT2A 155/4885MEN1 2323/4885MAPK1 1083/4885 |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | KMT2A 155/4885MEN1 2323/4885MAPK1 1083/4885 |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | KMT2A 155/4885MEN1 2323/4885MAPK1 1083/4885 |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | KMT2A 155/4885MEN1 2323/4885MAPK1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.